Europe Biosimilars Market Opportunity Outlook 2020 - 109 Clinical Pipeline Biosimilars & 20 Biosimilars Marketed

10 Nov, 2015, 08:10 ET from Research and Markets

DUBLIN, Nov. 10, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/zcbp58/europe) has announced the addition of the "Europe Biosimilars Market Opportunity Outlook 2020" report to their offering.

Burgeoning pressure on healthcare system has caused the regulators across the globe to look for suitable therapeutic options. Biologic drugs are commonly used for treatment of various diseases but they are costly and their alternative options are difficult to find. Biosimilars have come forth as new modality having lesser cost with equivalent therapeutic efficacy like biologics. They are introduced in market after patent expiry of biologics and Europe became the first market to allow commercialization of biosimilars. European Commission (EC) passed legislation in 2004 creating approval pathway (Directive 2001/83/EC Directive 2004/27/EC) for biosimilars. European Medicines Agency (EMA) approved first biosimilar in 2006, since then several biosimilars have been introduced in European market owing to applicability in numerous indications and higher cost arbitrage. In this way, European nations are expected to relieve burden from their healthcare system with the help of biosimilars.

Safety and efficacy are main concerns with biosimilars; EMA requires head-to-head comparison for ensuring pharmacological parameters. Ensuring similarity or high similarity in bioanalytical way decreases market winding time. Consequently, clinical trials could be conducted with higher confidence levels to ensure patient safety. Many biosimilars belonging to different categories for different indications has been introduced in past years. They have been able to erode profit margins of biologics in past decades. Wide acceptance could also be observed leading to higher prescription for biosimilars as compared to biologics. This scenario shows that biosimilars developers will have lots of commercialization opportunities in European market.

Extrapolation of biosimilars is allowed after establishing significant comparability with reference biologics. Depending on quality profile they are approved by EMA and biosimilar developers have to submit Risk Management Plan (RMP). This measure ensures that biosimilars entering in European market are harmless. Biosimilar developers from developing countries find it difficult to enter in European market as their fall short of EMA's standards. On the other hand, outsourced biosimilars products showing compliance with EMA's norms are allowed for commercialization. In this way, biosimilar developers from under developing countries find Europe as a suitable market place. Their competitive prices and highly developed manufacturing capabilities have also contributed in growth of European biosimilars market.

Europe Biosimilars Market Opportunity Outlook 2020 Report Highlight:

- Europe Biosimilars Market Outlook
- Europe Biosimilars Market Trend Analysis by Country
- Introduction of Biosimilars in European Market by Segment
- Clinical & Non Clinical Guidelines
- Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase
- Europe Biosimilar Clinical Pipeline: 109 Biosimilars
- Clinical Insight of Biosimilars Marketed in Europe
- Marketed Biosimilars in Europe: 20 Biosimilars

Key Topics Covered:

1. Europe Biosimilars Market Outlook

2. Europe Biosimilars Market Trend Analysis by Country

3. Introduction of Biosimilars in European Market by Segment

4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario

5. Europe Biosimilars Market Dynamics

6. Europe Biosimilars Market Future Outlook

7. Europe Biosmilars Market Regulatory Framework

8. Clinical & Non Clinical Guideline For Development of Biosimilars in Europe

9. Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase

10. Clinical Insight of Biosimilars Marketed in Europe

11. Suspended & Discontinued Biosimilars Clinical Insight

12. Competive Landscape

- Allergan
- Alvotech
- Amgen
- Biocad
- Bio-Ker
- BioXpress Therapeutics
- Boehringer Ingelheim
- Celltrion
- Cerbios Pharma
- Gedeon Richter
- Genentech
- Genexine
- Glycotope
- Harvest Moon Pharmaceuticals
- Hospira
- Janssen Biotech
- LFB Biotechnologies
- Mabion
- mAbxience
- Merck
- Momenta
- Novartis
- Perosphere
- Pfizer
- Pharmaceuticals
- Reliance Life Sciences
- Roche
- R-Pharm
- Samsung Bioepis
- Sanofi
- Teva Pharmaceutical
- Wockhardt

For more information visit http://www.researchandmarkets.com/research/zcbp58/europe

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com